Eisai and Biogen Launch Alzheimer's Drug Leqembi in China at USD24,800 per Year

Jun 27, 2024, 11:37 PM

Eisai and Biogen have launched their Alzheimer's treatment Leqembi in China, marking the third country after the United States and Japan to approve the drug. The treatment, which was approved by the Chinese regulator in January, is expected to be put into clinical use in Chinese hospitals, according to a hospital staffer in Shanghai. Leqembi, also known as Lecanemab, will cost CNY180,000 (USD24,800) per one-year cycle. This development signifies a significant step in the availability of advanced Alzheimer's treatments in China.